Say hello to MassDevice +3, a bite-sized view of the top three medtech stories of the day. This feature of MassDevice.com’s coverage highlights our 3 biggest and most influential stories from the day’s news to make sure you’re up to date on the headlines that continue to shape the medical device industry.
3. ‘Go-shop’ lapses without new rival for St. Jude’s $3B Thoratec buy
A 30-day “go-shop” period in St. Jude Medical’s pending, $3.4 billion acquisition of Thoratec lapsed without a 2nd suitor emerging, sending the companies’ stock prices down slightly.
The merger, medtech’s latest multi-billion union, calls for St. Jude to pay $63.50 in cash for each share of Pleasanton, Calif.-based Thoratec, funded using term loans and senior unsecured debt. Read more
2. TriVascular Technologies raises $10m, launches study of EVAR in women
Trivascular Technologies said it raised a $10 million funding round and launched a clinical study of endovascular aortic repair in women using its Ovation stent graft.
Santa Rosa, Calif.-based TriVascular said in a regulatory filing that it raised $10 million from 5 unnamed investors in a debt-and-warrants offering. The company, which won pre-market approval from the FDA this month for its Ovation iX device, raised $78 million in April 2014 with an initial public offering. Read more
1. Vital Therapies trial fails to meet endpoints
Vital Therapies said that the Phase III clinical trial of its Elad cell-based therapy treatment for liver failure did not meet primary or secondary endpoints and the company is shutting down 2 other clinical studies of the device.
The randomized, controlled, 203-patient trial examined the efficacy of the cell-based therapy in treating subjects with alcohol-induced liver decomposition. Read more
The post MassDevice.com +3 | The top 3 medtech stories for August 24, 2015 appeared first on MassDevice.
from MassDevice http://ift.tt/1EeyW7w
Cap comentari:
Publica un comentari a l'entrada